CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect, HydraSpace, and select toxSYN linker-payloads
Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin ), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V. (CEO: Peter van de Sande, Synaffix ), a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates (ADCs), today announced the signing of a license and option agreement.